HIV coreceptor phenotyping in the clinical setting.

Abstract excerpt

The introduction of CCR5 antagonists increases the options available for constructing antiretroviral regimens. However, this option is coupled with the caveat that patients should be tested for HIV coreceptor tropism prior to initiating CCR5 antagonist-based therapy. Failure to screen for CXCR4 usage increases the risk of using an ineffective drug, thus reducing the likelihood of viral suppression and increasing...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CCR5 Receptor Antagonists
• Share to HIV-1
• Share to Anti-HIV Agents